Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 43 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ULTRESA Clear all
Withdrawn Phase 2 Interventional

Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis

NCT02706236
View directory record Official record
Conditions
Pancreatitis
Interventions
Pancrelipase, placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

NCT00408317
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Ultrase® MT20, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Grand Rapids, Michigan • Cleveland, Ohio • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 22, 2026, 8:24 PM EDT
Terminated Phase 4 Interventional Results available

Pancreatic Enzyme Supplementation for Celiac Disease

NCT02475369
View directory record Official record
Conditions
Celiac Disease
Interventions
pancrelipase
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 4 Interventional Results available

A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT03924947
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pancrelipase
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Ventura, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 4 Interventional

Irritable Bowel Syndrome Evaluation and Treatment in Primary Care

NCT01641341
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Bifidobacterium infantis, Pancrelipase, Nitazoxanide, Placebo
Drug
Lead sponsor
American Academy of Family Physicians
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Lomita, California • Leawood, Kansas • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 22, 2026, 8:24 PM EDT
Not listed Not applicable Interventional

Zypan Functional Dyspepsia

NCT06320379
View directory record Official record
Conditions
Dyspepsia
Interventions
Zypan, Placebo Comparator
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

NCT00788593
View directory record Official record
Conditions
Chronic Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions
Placebo, EUR-1008 (APT-1008) High Dose, EUR-1008 (APT-1008) Low Dose
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 2 Interventional

An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)

NCT00559052
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency
Interventions
VIOKASE 16
Drug
Lead sponsor
Axcan Pharma
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Gainesville, Florida • Mayo Clinic- Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 3 Interventional

Efficacy of Pancrelipase on Postprandial Belching and Bloating.

NCT00266721
View directory record Official record
Conditions
Postprandial Bloating, Postprandial Belching, Postprandial Eructation
Interventions
Pancrelipase (Creon) 2 tablets with each meal
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2005 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 1 Interventional Results available

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

NCT01663272
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
CABOZANTINIB, gemcitabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 22, 2026, 8:24 PM EDT
Withdrawn Not applicable Interventional

Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients

NCT00663975
View directory record Official record
Conditions
Digestive System Diseases, Pancreatic Disease, Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
DCI 1020
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
Up to 2 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 4 Interventional Results available

PR-018: An Open-Label, Safety Extension of Study PR-011

NCT01131507
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Up to 12 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Jacksonville, Florida • Las Vegas, Nevada • Akron, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 22, 2026, 8:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

NCT05642962
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Carcinoma, Pancreatic Carcinoma, Pancreatic Carcinoma Metastatic, Pancreatic Carcinoma Non-resectable, Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
Pertzye
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

NCT05069597
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Pancreatitis
Interventions
CREON
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Mobile, Alabama • Madera, California • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 3 Interventional

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis

NCT00432861
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
PANCRECARB® (pancrelipase), Placebo
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
7 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)

NCT00690820
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions
Pancrelipase Delayed Release, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
7 Years to 11 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
10
States / cities
Iowa City, Iowa • Louisville, Kentucky • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2010 · Synced Oct 22, 2026, 8:24 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma

NCT03469258
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pancrelipase
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 22, 2026, 8:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

NCT02985801
View directory record Official record
Conditions
Pancreatic Insufficiency, Pancreatic Cancer, Pancreatic Enzyme Abnormality
Interventions
Pancrelipase, Placebo Oral Capsule
Drug
Lead sponsor
Massimo Raimondo, M.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 22, 2026, 8:24 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

NCT04098237
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Pancrelipase
Drug
Lead sponsor
Andrew Hendifar, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 22, 2026, 8:24 PM EDT